Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor Dismissal - The dismissal of Grant Thornton was linked to unresolved issues regarding segment reporting and internal controls, which the auditor communicated to management and the Audit Committee [5].

U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Wednesday.Shares of Winnebago Industries, Inc. (NYSE:WGO) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued FY26 guidance above estimates.Winnebago Industries posted adjusted earnings of 71 cents per share, beating market estimates of 53 cents per share. The company's quarterly sales came in at $777.300 million versus expectations of $727.824 million.Winne ...

[FORM 8-K Filing Details](index=1&type=section&id=FORM%208-K%20Filing%20Details) This section provides essential details about the Form 8-K filing, including registrant information and filing status [Registrant Information](index=1&type=section&id=Registrant%20Information) This section identifies Simulations Plus, Inc. as the registrant, detailing its incorporation state (California), commission file number, IRS Employer ID, principal executive offices, and telephone number - Registrant: **Simulations Plus, Inc.**[2](index=2&type=chunk) - Incorporation State: **California**[2](index=2&type=chunk) - Principal Executive Offices: **800 Park Offices Drive, Suite 401, Research Triangle Park, NC 27709**[2](index=2&type=chunk) [Filing Status and Securities](index=1&type=section&id=Filing%20Status%20and%20Securities) The filing indicates it is a Current Report under Section 13 or 15(d) of the Securities Exchange Act of 1934, filed on October 22, 2025, specifying the company's common stock (SLP) is registered on The Nasdaq Stock Market LLC and confirming the company is not an emerging growth company - Filing Date: **October 22, 2025**[2](index=2&type=chunk) - Trading Symbol: **SLP**, registered on **The Nasdaq Stock Market LLC**[3](index=3&type=chunk) - Not an **Emerging Growth Company**[4](index=4&type=chunk) [Current Report on Form 8-K](index=2&type=section&id=Current%20Report%20on%20Form%208-K) This section details the specific items of the Form 8-K filing, covering financial results, regulation disclosure, and filing status [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Simulations Plus, Inc. announced the issuance of a press release on October 22, 2025, detailing preliminary operational results for the fourth fiscal quarter ended August 31, 2025, and providing guidance for the fiscal year ending August 31, 2026, with this press release attached as Exhibit 99.1 - Company issued a press release on **October 22, 2025**[5](index=5&type=chunk) - Press release announced preliminary operational results for **Q4 FY2025** (ended August 31, 2025)[5](index=5&type=chunk) - Press release provided guidance and estimates for **FY2026** (ending August 31, 2026)[5](index=5&type=chunk) [Item 7.01 Regulation FD Disclosure](index=2&type=section&id=Item%207.01%20Regulation%20FD%20Disclosure) This section reiterates the disclosure made under Item 2.02, confirming the issuance of the press release on October 22, 2025, which contains preliminary Q4 FY2025 operational results and FY2026 guidance, furnished as Exhibit 99.1 - Reiteration of the press release issuance on **October 22, 2025**[5](index=5&type=chunk) - Press release covers preliminary **Q4 FY2025** results and **FY2026** guidance[5](index=5&type=chunk) [Information Furnished vs. Filed](index=2&type=section&id=Information%20Furnished%20vs.%20Filed) Items 2.02 and 7.01, along with Exhibit 99.1, are furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, meaning the information is not incorporated by reference into other SEC filings unless explicitly stated - Information in Items **2.02**, **7.01**, and **Exhibit 99.1** is 'furnished' not 'filed'[6](index=6&type=chunk) - Information shall not be incorporated by reference into other SEC filings unless expressly set forth[6](index=6&type=chunk) [Caution Regarding Forward-Looking Statements](index=2&type=section&id=CAUTION%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section warns about the inherent risks and uncertainties associated with forward-looking statements [Nature and Risks of Forward-Looking Statements](index=2&type=section&id=Nature%20and%20Risks%20of%20Forward-Looking%20Statements) This section warns that the report contains forward-looking statements, identified by terms like 'anticipates,' 'expects,' and 'estimates,' which involve substantial risks and uncertainties, and actual results may differ materially from those expressed or implied due to various factors, including those disclosed in other SEC filings - Report contains forward-looking statements identified by terms such as **'anticipates,' 'expects,' 'estimates,' 'believes'**[7](index=7&type=chunk) - Forward-looking statements involve **substantial risks and uncertainties**[7](index=7&type=chunk) - Actual results, performance, or achievements may differ materially from those expressed or implied by forward-looking statements due to **known and unknown risks**[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the financial statements and exhibits included in the Form 8-K filing [Exhibits List](index=2&type=section&id=Exhibits%20List) This section lists the exhibits accompanying the Form 8-K, where Exhibit 99.1 is the Press Release dated October 22, 2025, and Exhibit 104 is the Cover Page Interactive Data File Exhibits List | Exhibit Number | Description | |---|---| | 99.1 | Press Release - October 22, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=3&type=section&id=SIGNATURES) This section confirms the official signing of the report by an authorized officer [Report Signatories](index=3&type=section&id=Report%20Signatories) The report was duly signed on behalf of Simulations Plus, Inc. by Will Frederick, Executive Vice President and Chief Financial Officer, on October 22, 2025, in accordance with the Securities Exchange Act of 1934 requirements - Report signed by **Will Frederick, Executive Vice President and Chief Financial Officer**[13](index=13&type=chunk) - Signing Date: **October 22, 2025**[13](index=13&type=chunk)

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus†or the "Company†), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows: Fiscal 2025 Preliminary Fiscal 2026 Guidance Revenue  . ...

Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company specializing in modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Stock Impact - On April 15, 2025, Simulations Plus hired Grant Thornton LLP as its new auditor, which was followed by a significant stock price drop after the company announced disappointing preliminary financial results for Q3 2025 on June 11, 2025, with a decline of over 24% from $26.44 to $20.05 per share [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results on July 14, 2025, and subsequently dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Auditor Dispute - Grant Thornton disagreed with Simulations Plus's characterizations regarding internal controls and reporting, leading to further stock price decline of nearly 26% from $17.47 to $12.97 per share following the announcement of the impairment charge and auditor findings [5].

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but the Conestoga Small Cap Composite underperformed the Russell 2000 Growth Index, returning -1.4% compared to the Index's 12.2% gain [1] - The gains in the Russell 2000 Growth Index were primarily driven by low-quality stocks, particularly unprofitable, high-beta names [1] Company Analysis: Simulations Plus, Inc. (NASDAQ:SLP) - Simulations Plus, Inc. specializes in drug discovery and development software that leverages AI and machine learning for modeling and simulation [2] - The stock had a one-month return of 0.98% but experienced a significant decline of 54.90% over the past 52 weeks, closing at $15.40 per share with a market capitalization of $309.957 million on October 17, 2025 [2] - The company has faced slowing revenue growth due to funding pressures on smaller biotech customers, which has reduced demand for its products [3] - Despite its potential, the valuation of Simulations Plus remains elevated compared to peers, raising concerns about risk/reward dynamics [3] - Increased competition in drug-modeling software and inconsistent performance in consulting services may further pressure the company's margins [3] - Conestoga Capital Advisors decided to sell the stock due to near-term headwinds outweighing long-term potential [3] Hedge Fund Interest - Simulations Plus, Inc. was held by 11 hedge fund portfolios at the end of Q2 2025, a decrease from 13 in the previous quarter [4] - While acknowledging the potential of Simulations Plus, the company believes that other AI stocks present greater upside potential with less downside risk [4]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and indicated ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor, Grant Thornton, due to unresolved matters regarding segment reporting and internal controls [5] - Following the impairment charge and auditor dismissal, the stock price fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1 - The investigation is focused on the potential impact of misleading information on Simulations Plus shareholders [1] - Shareholders who purchased Simulations Plus securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor's Findings - Grant Thornton identified unresolved issues regarding segment reporting and internal controls, which contradicted Simulations Plus's statements about its financial reporting [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings in June 2024, aiming to double its total addressable market and enhance sales [2][3]. Financial Reporting Issues - Simulations Plus claimed effective internal controls over financial reporting; however, it appears the company struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, which later raised concerns regarding the company's financial reporting [4][5]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025 on June 11, 2025, Simulations Plus's stock price dropped by over 24%, from $26.44 to $20.05 per share [4]. - The company reported a $77.2 million charge related to prior acquisitions on July 14, 2025, leading to a further decline in stock price by nearly 26%, from $17.47 to $12.97 per share [5].